公开(公告)号：US20230399641A1

公开(公告)日：2023-12-14

申请号：US18036399

申请日：2021-11-11

Applicant: SHANGHAITECH UNIVERSITY

Inventor： Jia CHEN ,  Bei YANG ,  Li YANG ,  Xiaosa LI ,  Xiao WANG ,  Wenwen ZHAO ,  Lina ZHOU ,  Jifang LI

IPC: C12N15/11 ,  C12N9/22 ,  C12N9/12 ,  C12N15/90

CPC classification number: C12N15/111 ,  C12N9/22 ,  C12N9/1276 ,  C12Y207/07049 ,  C12N15/907 ,  C12N2310/20 ,  C07K2319/00

Abstract: Provided are compositions and methods for enhanced prime editing, which include a pegRNA that encodes a target mutation in a target protein, along with one or more nearby silent or conservative mutations. These silent mutations can increase the editing efficiency, without causing a change to the target protein sequence. Also provided are compositions and methods of using the improved prime editing for preventing or treating infections by SARS-CoV or SARS-CoV-2.

公开(公告)号：US20240117335A1

公开(公告)日：2024-04-11

申请号：US18525555

申请日：2023-11-30

Applicant: ShanghaiTech University

Inventor： Jia CHEN ,  Li Yang ,  Xingxu Huang ,  Bei Yang ,  Xiao Wang ,  Jianan Li

IPC: C12N9/78 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90

CPC classification number: C12N9/78 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  C12Y305/04 ,  C07K2319/00 ,  C12N2310/20 ,  C12N2800/80

Abstract: Provided are fusion proteins that include an apolipoprotein B mRNA editing enzyme catalytic subunit 3A (APOBEC3A) and a clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) protein, optionally further with uracil glycosylase inhibitor (UGI). Such a fusion protein is able to conduct base editing in DNA by deaminating cytosine to uracil, even when the cytosine is in a GpC context or is methylated.

公开(公告)号：US20240189457A1

公开(公告)日：2024-06-13

申请号：US18553729

申请日：2022-04-02

Applicant: ShanghaiTech University

Inventor： Jia CHEN ,  Bei YANG ,  Li YANG ,  Wenyan HAN ,  Shangwu SUN ,  Ying ZHANG

IPC: A61K48/00 ,  A61K38/17 ,  C12N5/078 ,  C12N5/0789 ,  C12N9/22 ,  C12N9/78 ,  C12N15/11

CPC classification number: A61K48/005 ,  A61K38/1722 ,  C12N5/0641 ,  C12N5/0647 ,  C12N9/22 ,  C12N9/78 ,  C12N15/111 ,  C07K2319/50 ,  C12N2310/20 ,  C12Y305/04005

Abstract: Provided are gene therapy technologies, including specifically designed and tested guide RNA sequences for improved base editors, useful for increasing the expression of the gamma-globin gene. The guide RNA sequences may target the BCL11A erythroid enhancer or the gamma-globin promoter, or both at the same time. The base editors can include nucleobase deaminase inhibitor that inhibits the editing activity of the base editors until they are bound to the target sites. These gene therapy technologies are useful for treating diseases including beta-thalassemia and sickle cell anemia, among others.